TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Tak-228 & Tak-117|DRUG: Cisplatin & Nab Paclitaxel
Sponsor: Joyce O'Shaughnessy
Collaborators: Takeda